Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)
Stopped Involving changes to the primary endpoint, it is difficult to unify the evaluation criteria for subjects' endpoints before and after the change.
Conditions
- Renal Cell Carcinoma (RCC)
Interventions
- DRUG: Toripalimab
- DRUG: Lenvatinib
Sponsor
Jinling Hospital, China